Compare Viatris Inc (VTRS) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs WD 40 Company — how do they compare? Viatris Inc trades at $16.23 (market cap $18.69B), while WD 40 Company trades at $232.54 (market cap $3.13B). The key difference: Viatris Inc is far larger — about 6× WD 40 Company's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| VTRS | WDFC | |
|---|---|---|
Market Cap | $18.69B | $3.13B |
Sector | Health | Technology |
52-Week High | $17.86 | $264.91 |
52-Week Low | $9.49 | $187.52 |
Enterprise Value | $30.80B | $3.18B |
Dividend Yield | 2.95% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
WD-40 Company (WDFC) trades at $232.9, down 0.69% today, with strong technical momentum showing bullish moving averages and key support at $230. The company reported impressive Q2 2026 earnings of $2.33 per share, beating estimates by 49%, while revenue growth continues with 2026 projections at $675 million. Recent news highlights institutional buying and positive analyst coverage, though valuation metrics remain elevated with a P/E of 35.39.
WDFC demonstrates solid fundamentals with consistent profitability (13.22% net margin) and strong brand positioning, but faces margin pressure from rising input costs. Analyst sentiment is mixed with 71% hold ratings, suggesting cautious optimism. Key risks include valuation concerns and cost inflation, while the company's dividend policy and global brand recognition provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
